Apollo Hospitals Enterprise Ltd (AHEL) on Friday (September 12) said it will purchase International Finance Corporation’s (IFC) 31% holding in its subsidiary, Apollo Health and Lifestyle Ltd (AHLL), for ₹1,254 crore.
With this transaction, AHLL will become a wholly owned subsidiary of AHEL, of which 99.42% will be held directly by Apollo and the rest reserved for an employee stock option (ESOP) pool.
According to Apollo, the acquisition will help streamline operations, enhance return on capital employed (ROCE), and drive disciplined expansion across AHLL’s four business verticals.
“This is a decisive move that enables sharper capital allocation and greater focus on high-potential areas,” said Suneeta Reddy, Managing Director of Apollo Hospitals. “We expect AHLL to emerge as a strong growth driver within Apollo’s integrated healthcare ecosystem.”
AHLL operates across four key segments: diagnostics and primary care, women’s health and birthing (Apollo Cradle), ambulatory care, and networks for dialysis and dental services. IFC had first invested in AHLL in December 2016, acquiring 29.03% for ₹450 crore, split equally between IFC’s own funds and the IFC Emerging Asia Fund managed by IFC Asset Management Company.
In FY25, AHLL reported revenues of ₹1,553.5 crore, up from ₹1,365.3 crore the previous year. The company is aiming for high-teen CAGR growth in diagnostics and primary care, fueled by genomics, molecular testing, and personalized health screenings.
“With AHLL now fully under Apollo, we can sharpen our strategic priorities and scale the business more efficiently,” added Sangita Reddy, Joint Managing Director. “The stronger focus will also allow faster innovation and delivery of personalized, accessible, and future-ready healthcare models.”
Oncology Expansion in Gurugram
Alongside the acquisition, Apollo announced a ₹573 crore investment to build a 100-bed Comprehensive Oncology Centre in Gurugram, funded entirely through internal accruals. The centre will feature the advanced Proteus One single gantry Proton Beam Therapy system Apollo’s third proton therapy installation after Chennai and Hyderabad.
The Gurugram facility will form part of Phase 2 of Apollo’s upcoming 500-bed hospital in the city, scheduled for completion by FY29.
“With this addition, Apollo Proton Cancer Centres strengthen their global leadership in proton therapy,” said Dr. Prathap C Reddy, Founder and Chairman of Apollo Hospitals.
Apollo plans to double its oncology business to over ₹5,000 crore within the next 3–4 years, leveraging advanced personalized medicine, robotics, immunotherapy, genomics-driven treatments, and CAR-T cell therapies.